Summary

Article Metadata

Iovance Biotherapeutics Stock Surges

This is a news story, published by Yahoo Finance, that relates primarily to Amtagvi news.

Amtagvi news

For more Amtagvi news, you can click here:

more Amtagvi news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

new cancer drug Amtagvi

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Iovance Biotherapeutics Shares news, veteran biopharma investors none news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Iovance Biotherapeutics

The Motley Fool

The Motley Fool

•

Shares of Iovance Biotherapeutics are soaring after better-than-expected Q2 results

The Motley Fool

Summary

Nutrition label

72% Informative

Shares of Iovance Biotherapeutics are up 24.2% as of 11:20 a.m. ET today in response to an impressive second-quarter report.

The company's new cancer drug Amtagvi (also known as lifileucel) is off to a solid start.

The potential for the drug is enormous; researchers with Global Data suggest it could be producing annual sales of more than $800 million by 2029 .

VR Score

69

Informative language

71

Neutral language

32

Article tone

semi-formal

Language

English

Language complexity

49

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

7

https://www.fool.com/author/4549/https://www.fool.com/terms/r/revenue/?utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=134125b3-b6a6-430a-aa91-a2ad0334e765 https://www.fool.com/legal/fool-disclosure-policy/https://api.fool.com/infotron/infotrack/click?apikey=35527423-a535-4519-a07f-20014582e03e&impression=4c89eb87-e639-4286-b797-f615e8f9de5d&url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fe-foolcom-sa-bbn-dyn%3Faid%3D8867%26source%3Disaeditxt0010895%26ftm_cam%3Dsa-bbn-evergreen%26ftm_pit%3D13885%26ftm_veh%3Darticle_pitch_feed_yahoo%26company%3DIovance%2520Biotherapeutics&utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=134125b3-b6a6-430a-aa91-a2ad0334e765 https://www.fool.com/investing/2024/08/09/why-iovance-biotherapeutics-shares-are-soaring-tod/?utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=134125b3-b6a6-430a-aa91-a2ad0334e765 https://api.fool.com/infotron/infotrack/click?apikey=35527423-a535-4519-a07f-20014582e03e&impression=4c89eb87-e639-4286-b797-f615e8f9de5d&url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fe-foolcom-sa-bbn-dyn%3Faid%3D8867%26amp%253Bsource%3Disaeditxt0010895%26ftm_cam%3Dsa-bbn-evergreen%26ftm_veh%3Darticle_pitch_feed_yahoo%26ftm_pit%3D13885&utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=134125b3-b6a6-430a-aa91-a2ad0334e765 https://www.fool.com/investing/2024/07/31/iovance-biotherapeutics-attracts-a-downgrade-is-it/?utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=134125b3-b6a6-430a-aa91-a2ad0334e765

Source diversity

2

www.fool.com api.fool.com

Affiliate links

no affiliate links

Read full article